Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Profound Medical (PROF) EBIT (2019 - 2026)

Profound Medical has reported EBIT over the past 7 years, most recently at $27.5 million for Q4 2025.

  • For Q4 2025, EBIT rose 429.98% year-over-year to $27.5 million; the TTM value through Dec 2025 reached -$6.3 million, up 80.8%, while the annual FY2025 figure was -$6.3 million, 80.8% up from the prior year.
  • EBIT for Q4 2025 was $27.5 million at Profound Medical, up from -$8.9 million in the prior quarter.
  • Over five years, EBIT peaked at $27.5 million in Q4 2025 and troughed at -$55.4 million in Q4 2022.
  • A 5-year average of -$6.5 million and a median of -$729000.0 in 2021 define the central range for EBIT.
  • On a YoY basis, EBIT climbed as much as 148006037.66% in 2021 and fell as far as 369.6% in 2021.
  • Year by year, EBIT stood at -$50.9 million in 2021, then dropped by 9.0% to -$55.4 million in 2022, then rose by 12.53% to -$48.5 million in 2023, then surged by 82.79% to -$8.3 million in 2024, then soared by 429.98% to $27.5 million in 2025.
  • Business Quant data shows EBIT for PROF at $27.5 million in Q4 2025, -$8.9 million in Q3 2025, and -$13.8 million in Q2 2025.